Research graph
References from TP53 Mutation Heterogeneity Refines Prognostic Stratification in IDH ‐Wildtype Glioma. Local targets link to admitted publications; unresolved targets remain external evidence.
Glioblastoma and Other Malignant Gliomas: A Clinical Review
10.1001/jama.2013.280319 · 2013 · External reference
The PODNL1/AKT/β‐Catenin Signaling Axis Mediates Glioma Progression and Sensitivity to Temozolomide
10.1016/j.fmre.2023.03.005 · 2025 · External reference
The Importance of Integrating Surgical Resection Into Preclinical Glioblastoma Modeling
10.1158/1078-0432.ccr-25-0788 · 2025 · External reference
Clinical Practice Guidelines for the Management of Adult Diffuse Gliomas
10.1016/j.canlet.2020.10.050 · 2021 · External reference
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary
10.1007/s00401-016-1545-1 · 2016 · External reference
TP53 Mutations and Survival in Patients With Histologically Defined Glioblastoma, IDH‐Wildtype
10.1016/j.prp.2024.155516 · 2024 · External reference
TP53, ATRX Alterations, and Low Tumor Mutation Load Feature IDH‐Wildtype Giant Cell Glioblastoma Despite Exceptional Ultra‐Mutated Tumors
10.1093/noajnl/vdz059 · 2020 · External reference
p53: 800 Million Years of Evolution and 40 Years of Discovery
10.1038/s41568-020-0262-1 · 2020 · External reference
Prognosis of TP53 and Its Concomitant EGFR Mutation in Lung Cancer Especially Non‐Small Cell Lung Cancer
10.31557/apjcp.2025.26.1.17 · 2025 · External reference
Mutant p53 in Cancer: From Molecular Mechanism to Therapeutic Modulation
10.1038/s41419-022-05408-1 · 2022 · External reference
Targeting p53 Gain‐of‐Function Activity in Cancer Therapy: A Cautionary Tale
10.1038/s41418-023-01253-7 · 2024 · External reference
Mutant p53 Gain of Function Mediates Cancer Immune Escape That is Counteracted by APR‐246
10.1038/s41416-022-01971-8 · 2022 · External reference
TP53 Mutation Variant Allele Frequency of ≥ 10% is Associated With Poor Prognosis in Therapy‐Related Myeloid Neoplasms
10.1038/s41408-023-00821-x · 2023 · External reference
The Tumor Suppressor p53: From Structures to Drug Discovery
10.1101/cshperspect.a000919 · 2010 · External reference
Protein‐DNA Binding Correlates With Structural Thermostability for the Full‐Length Human p53 Protein
10.1021/bi002088z · 2001 · External reference
Molecular Alterations in IDH‐Mutant Astrocytoma: A Multi‐Institutional Retrospective Study
10.1093/noajnl/vdaf088 · 2025 · External reference
IDH‐Mutated Astrocytomas With 19q‐Loss Constitute a Subgroup That Confers Better Prognosis
10.1111/cas.13635 · 2018 · External reference
Prognostic Impact of PDGFRA Gain/Amplification and MGMT Promoter Methylation Status in Patients With IDH Wild‐Type Glioblastoma
10.1093/noajnl/vdac097 · 2022 · External reference
Association of TP53 Alteration With Tissue Specificity and Patient Outcome of IDH1‐Mutant Glioma
10.3390/cells10082116 · 2021 · External reference
Convergent TP53 Loss and Evolvability in Cancer
10.1186/s12862-023-02146-6 · 2023 · External reference
Longitudinal Multimodal Profiling of IDH‐Wildtype Glioblastoma Reveals the Molecular Evolution and Cellular Phenotypes Underlying Prognostically Different Treatment Responses
10.1093/neuonc/noae214 · 2025 · External reference
Impact of Genotype and Morphology on the Prognosis Of Glioblastoma
10.1093/jnen/61.4.321 · 2002 · External reference
Evidence‐Based Risk Stratification of Myeloid Neoplasms Harboring TP53 Mutations
10.1182/bloodadvances.2024015238 · 2025 · External reference
Impact of TP53 Mutation Variant Allele Frequency on Phenotype and Outcomes in Myelodysplastic Syndromes
10.1038/leu.2015.304 · 2016 · External reference
TP53‐Mutant Variant Allele Frequency and Cytogenetics Determine Prognostic Groups in MDS/AML for Transplantation
10.1182/bloodadvances.2024014499 · 2025 · External reference
Tetramer Formation of Tumor Suppressor Protein p53: Structure, Function, and Applications
10.1002/bip.22772 · 2016 · External reference
TP53 Mutations in Cancer: Molecular Features and Therapeutic Opportunities (Review)
10.3892/ijmm.2024.5448 · 2025 · External reference
Unraveling the Unique Amyloid‐Like Aggregation Behavior of the Tumor Suppressor p53 Mutants in Human Cancers
10.1016/j.ijbiomac.2025.143883 · 2025 · External reference
Drugging p53: Barriers, Criteria, and Prospects
10.1158/2159-8290.cd-24-0837 · 2024 · External reference
Structural Effects of the L145Q, V157F, and R282W Cancer‐Associated Mutations in the p53 DNA‐Binding Core Domain
10.1021/bi200192j · 2011 · External reference
A Gain‐of‐Function Mutant p53‐HSF1 Feed Forward Circuit Governs Adaptation of Cancer Cells to Proteotoxic Stress
10.1038/cddis.2014.158 · 2014 · External reference
Influence of TP53 Mutation on Efficacy and Survival in Advanced EGFR‐Mutant Non‐Small Cell Lung Cancer Patients Treated With Third‐Generation EGFR Tyrosine Kinase Inhibitors
2024 · External reference
Targeting p53 Pathways: Mechanisms, Structures, and Advances In Therapy
10.1038/s41392-023-01347-1 · 2023 · External reference
PCSK9 Promotes Progression of Anaplastic Thyroid Cancer Through E‐Cadherin Endocytosis
10.1038/s41419-025-07690-1 · 2025 · External reference
TP53 Mutation and Immunohistochemical p53 Expression Characteristics in Diffuse Large B‐Cell Lymphoma
10.3389/fonc.2025.1550207 · 2025 · External reference
Albumin‐Bound Paclitaxel Augment Temozolomide Treatment Sensitivity of Glioblastoma Cells by Disrupting DNA Damage Repair and Promoting Ferroptosis
10.1186/s13046-023-02843-6 · 2023 · External reference
Effect of Piezo1 Overexpression on Peritumoral Brain Edema in Glioblastomas
10.3174/ajnr.a6638 · 2020 · External reference
